Carparts.Com Inc vs Regeneron Pharmaceuticals Inc — how do they compare? Carparts.Com Inc trades at $8.61 (market cap $66.42M), while Regeneron Pharmaceuticals Inc trades at $744.35 (market cap $76.14B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 1146.3× Carparts.Com Inc's market cap, and Regeneron Pharmaceuticals Inc pays a 0.51% dividend while Carparts.Com Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Carparts.Com Inc for 45 Days and Regeneron Pharmaceuticals Inc for 107 Days on average.
| PRTS | REGN | |
|---|---|---|
Market Cap | $66.42M | $76.14B |
Volume | 40,287 | 500,239 |
Sector | Consumer Cyclical | Health |
52-Week High | $10.00 | $852.03 |
52-Week Low | $3.88 | $557.73 |
Typical Hold Time | 45 Days | 107 Days |
Enterprise Value | $79.39M | $70.85B |
Dividend Yield | — | 0.51% |
Signals from Pluang's Aura AI — not financial advice
CarParts.com (PRTS) trades at $8.695, up 0.99% on the day, with a bullish technical outlook supported by positive moving average signals. The company shows improving quarterly earnings performance, beating estimates in recent quarters, though it remains unprofitable with negative margins. Analyst sentiment is positive with 60% buy ratings, while recent news highlights the company's data-driven competitive strategy in the auto parts e-commerce sector.
The stock presents a speculative opportunity given its low P/S ratio of 0.11 and consistent earnings beats, but faces significant fundamental challenges including negative cash flow, declining revenue trends, and persistent losses. Key risks include execution challenges in achieving profitability and competitive pressures in the online auto parts market.
Regeneron Pharmaceuticals (REGN) trades at $739.28, down 0.38% on the day, with a bearish technical signal and neutral oscillators. The company shows strong fundamentals with a P/E of 18.3, net income margin of 27.86%, and consistent earnings beats in recent quarters. Recent news highlights a major $8 billion immunology alliance expansion with Sanofi, including a $1 billion upfront payment, reinforcing its pipeline strength and long-term growth prospects.
The outlook remains positive driven by robust profitability, strategic collaborations, and a bullish analyst consensus with a $849.84 price target. Key risks include competitive pressures in key drug markets and reliance on successful clinical trial outcomes. Institutional sentiment is strong with no sell ratings, supporting a favorable risk-reward profile for investors seeking exposure to biopharmaceutical innovation.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
CarParts.com Inc is an online provider of automotive aftermarket parts and repair information. The company principally sells its products to individual consumers through its network of websites and online marketplaces. The company's products consist of collision parts serving the body repair market, engine parts to serve the replacement parts market, and performance parts and accessories.
Read more on PRTS →Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →